Plain-English translation of NCT07673861 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial tests whether a blood test called ctDNA (circulating tumor DNA) can help doctors better understand why your cancer stopped responding to treatment and guide them toward the right next therapy for you. The test works by analyzing cancer DNA that naturally leaks into your bloodstream, giving doctors information about your cancer without needing a tissue biopsy. The study will include 100 patients with five different types of cancer to see if this blood test can deliver more personalized, precise cancer care.
Standard cancer tests sometimes cannot identify why a patient's cancer has become resistant to treatment or what the best next step should be. This study aims to show that the blood test can fill that gap, helping doctors find a better matched treatment or clinical trial for each patient more quickly and accurately.
You likely qualify if…
You likely don't qualify if…
You will have a single blood sample taken at The Royal Marsden Hospital, which will be analyzed using their ctDNA test. Your results will then be reviewed by a specialist advisory board who will determine whether the blood test findings can help identify a standard treatment matched to your cancer's genetics, a relevant clinical trial, or provide other prognostic information that wasn't available through routine testing. The study does not involve taking new medications—it is designed to help guide your existing or future treatment decisions.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United Kingdom